Latest News
Protagonist Therapeutics awards stock options to new EVP of clinical operations and pharmacology Suneel Gupta, PhD
17 January 2019 - Biopharmaceutical company Protagonist Therapeutics Inc (Nasdaq:PTGX) on Wednesday announced the grant of stock options to newly appointed executive vice president of clinical operations and pharmacology Suneel Gupta, PhD, in accorda...
Targovax wins patent for Mutant-RAS neoantigen platform lead products in Europe
17 January 2019 - Immuno-oncology company Targovax ASA (OSE:TRVX) revealed on Wednesday the receipt of the European patent that will protect its mutant-RAS specific neoantigen peptides, mutant RAS specific T cells and vaccines TG01 and TG02, for the ...
Therachon awarded US FDA's orphan drug designation for apraglutide for the treatment of short bowel syndrome
17 January 2019 - Biotechnology company Therachon AG said on Wednesday that it has passed the US Food and Drug Administration's (FDA) orphan drug designation for apraglutide for the treatment of short bowel syndrome (SBS).Short Bowel Syndrome (S...
Bridge wins US FDA's orphan drug designation for BBT-877 in IPF, with first-in-human clinical study set to begin next month
17 January 2019 - Biotech company Bridge Biotherapeutics Inc revealed on Wednesday the receipt of the US Food and Drug Administration's (FDA) orphan drug designation (ODD) to promote the development of the drug candidate BBT-877 for the treatmen...
Acurx Pharmaceuticals LLC awarded the US FDA's fast track designation for 362E for Clostridium difficile Infection
17 January 2019 - Biopharmaceutical company Acurx Pharmaceuticals LLC revealed on Wednesday the receipt of the US Food and Drug Administration's Fast Track designation to facilitate the development and expedite the regulatory pathway of the inve...